Idiopathic Intracranial Hypertension Market

Market Overview:

The 7 major idiopathic intracranial hypertension markets reached a value of USD 525 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,030.4 Million by 2035, exhibiting a growth rate (CAGR) of 6.32% during 2025-2035.

The idiopathic intracranial hypertension (IIH) market has been comprehensively analyzed in IMARC’s new report titled “Idiopathic Intracranial Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035”. Idiopathic intracranial hypertension (IIH) refers to a neurological disorder of unknown etiology characterized by chronically elevated intracranial pressure (ICP). This condition is caused by an abnormal increase in the pressure of the cerebrospinal fluid (CSF) that surrounds the brain and spinal cord. Idiopathic intracranial hypertension is primarily diagnosed in overweight or obese women of childbearing age, but it can also occur in men, children, and people who are not overweight. The most common symptoms of IIH are headache, which is typically a severe and constant pain that is often worse in the morning and at night, and vision problems, including double vision, blurring, and blind spots. Other symptoms may include nausea, vomiting, ringing in the ears, and problems with balance. In some cases, IIH can lead to permanent vision loss if not treated promptly. Diagnosis of IIH is made through a combination of medical history, physical examination, and imaging studies. Several diagnostic tests are used to rule out a tumor and find the cause of symptoms, including a brain CT scan or MRI, an eye exam to check for swelling near the optic nerve, and a spinal tap (lumbar puncture) to evaluate CSF. Treatment for IIH typically involves a combination of medical and surgical options.

The increasing prevalence of obesity, which is a major risk factor for IIH, is primarily driving the global idiopathic intracranial hypertension market. In addition to this, the escalating utilization of lumbar puncture to measure the opening pressure, as well as to obtain CSF which examines abnormal cells, infections, antibody levels, glucose levels, and protein levels for diagnosing IIH is further augmenting the market growth. Moreover, the widespread adoption of several medications, such as acetazolamide, topiramate, furosemide, etc., to reduce cerebrospinal fluid (CSF) production and/or increase CSF absorption is creating a positive outlook for the market. Apart from this, the rising popularity of surgical therapies among patients who have failed medications or have significant loss of peripheral or central vision is also bolstering the market growth. For instance, optic nerve sheath fenestration (ONSF), which involves making minor cuts in the sheath surrounding the optic nerve to decrease pressure on the nerve, is often employed for treating IIH. Furthermore, the growing importance of weight loss as an effective means of reducing papilledema and, consequently, the risk of progressive blindness, is also acting as a significant growth-inducing factor. Patients are encouraged to enroll in a rigorous weight loss program, ideally using a multidisciplinary approach that includes diet and exercise along with psychological and lifestyle counseling. Besides this, several key players are making extensive investments in introducing novel medications to reduce disease symptoms, prevent vision loss, and improve quality of life. This, in turn, is expected to drive the global idiopathic intracranial hypertension market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the idiopathic intracranial hypertension market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for idiopathic intracranial hypertension and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the idiopathic intracranial hypertension market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the idiopathic intracranial hypertension market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the idiopathic intracranial hypertension market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current idiopathic intracranial hypertension marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the idiopathic intracranial hypertension market performed so far, and how will it perform in the coming years?
• What are the market shares of various therapeutic segments in 2024, and how are they expected to perform till 2035?
• What was the country-wise size of the idiopathic intracranial hypertension market across the seven major markets in 2024, and what will it look like in 2035?
• What is the growth rate of the idiopathic intracranial hypertension market across the seven major markets, and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of idiopathic intracranial hypertension across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of idiopathic intracranial hypertension by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of idiopathic intracranial hypertension by gender across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of idiopathic intracranial hypertension by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with idiopathic intracranial hypertension across the seven major markets?
• What is the size of the idiopathic intracranial hypertension patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of idiopathic intracranial hypertension?
• What will be the growth rate of patients across the seven major markets?
   

Idiopathic Intracranial Hypertension: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs, and what is their market performance?
• What are the key pipeline drugs, and how are they expected to perform in the coming years?
• How safe are the current marketed drugs, and what are their efficacies?
• How safe are the late-stage pipeline drugs, and what are their efficacies?
• What are the current treatment guidelines for idiopathic intracranial hypertension drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the idiopathic intracranial hypertension market?
• What are the key regulatory events related to the idiopathic intracranial hypertension market?
• What is the structure of clinical trial landscape by status related to the idiopathic intracranial hypertension market?
• What is the structure of clinical trial landscape by phase related to idiopathic intracranial hypertension market?
• What is the structure of clinical trial landscape by route of administration related to the idiopathic intracranial hypertension market?